[1]JUNGST C, BERG T, CHENG J, et al.Intrahepatic cholestasis in common chronic liver diseases[J].Eur J Clin Invest, 2013, 43 (10) :1069-1083.
|
[2]KAR SP, SELDIN MF, CHEN W, et al.Pathway-based analysis of primary biliary cirrhosis genome-wide association studies[J].Genes Immun, 2013, 14 (3) :179-186.
|
[3]LEUNG PS, WANG J, NAIYANETR P, et al.Environment and primary biliary cirrhosis:electrophilic drugs and the induction of AMA[J].J Autoimmun, 2013, 41:79-86.
|
[4]IMAM MH, LINDOR KD.The natural history of primary biliary cirrhosis[J].Semin Liver Dis, 2014, 34 (3) :329-333.
|
[5]ZHANG ZY, WANG YP, ZHOU YN.Advances in diagnosis and treatment of primary biliary cholangitis[J].J Clin Hepatol, 2016, 32 (10) :2016-2020. (in Chinese) 张臻英, 王玉平, 周永宁.原发性胆汁性胆管炎诊治进展[J].临床肝胆病杂志, 2016, 32 (10) :2016-2020.
|
[6]DUWAERTS CC, GEHRING S, CHENG CW, et al.Contrasting responses of Kupffer cells and inflammatory mononuclear phagocytes to biliary obstruction in a mouse model of cholestatic liver injury[J].Liver Int, 2013, 33 (2) :255-265.
|
[7]ALLER MA, ARIAS JL, PRIETO I, et al.Bile duct ligation:step-by-step to cholangiocyte inflammatory tumorigenesis[J].Eur JGastroenterol Hepatol, 2010, 22 (6) :651-661.
|
[8]WAKABAYASHI K, LIAN ZX, LEUNG PS, et al.Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease[J].Hepatology, 2008, 48 (2) :531-540.
|
[9]FICKERT P, STOGER U, FUCHSBICHLER A, et al.A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis[J].Am J Pathol, 2007, 171 (2) :525-536.
|
[10]OKADA C, AKBAR SM, HORIIKE N, et al.Early development of primary biliary cirrhosis in female C57BL/6 mice because of poly I∶Cadministration[J].Liver Int, 2005, 25 (3) :595-603.
|
[11]GUO XX, LI LX, WU YP, et al.Establishment of a mouse model of early primary biliary cirrhosis by polyinosinic-polycytidylic acid[J].J Pract Hepatol, 2014, 17 (6) :619-622. (in Chinese) 郭晓霞, 李良学, 武玉鹏, 等.聚肌胞苷酸诱导的早期原发性胆汁性肝硬化小鼠模型的建立[J].实用肝脏病杂志, 2014, 17 (6) :619-622.
|
[12]SONG G, HU C, ZHU H, et al.Comparative proteomics study on liver mitochondria of primary biliary cirrhosis mouse model[J].BMC Gastroenterol, 2013, 13:64.
|
[13]AMBROSINI YM, YANG GX, ZHANG W, et al.The multi-hit hypothesis of primary biliary cirrhosis:polyinosinic-polycytidylic acid (poly I∶C) and murine autoimmune cholangitis[J].Clin Exp Immunol, 2011, 166 (1) :110-120.
|
[14]PADGETT KA, SELMI C, KENNY TP, et al.Phylogenetic and immunological definition of four lipoylated proteins from Novosphingobium aromaticivorans, implications for primary biliary cirrhosis[J].J Autoimmun, 2005, 24 (3) :209-219.
|
[15]MATTNER J, SAVAGE PB, LEUNG P, et al.Liver autoimmunity triggered by microbial activation of natural killer T cells[J].Cell Host Microbe, 2008, 3 (5) :304-315.
|
[16]WANG J, SHAN Y, JIANG Z, et al.High frequencies of activated B cells and T follicular helper cells are correlated with disease activity in patients with new-onset rheumatoid arthritis[J].Clin Exp Immunol, 2013, 174 (2) :212-220.
|
[17]WANG JJ, YANG GX, ZHANG WC, et al.Escherichia coli infection induces autoimmune cholangitis and anti-mitochondrial antibodies in non-obese diabetic (NOD) .B6 (Idd10/Idd18) mice[J].Clin Exp Immunol, 2014, 175 (2) :192-201.
|
[18]BOGDANOS DP, BAUM H, GRASSO A, et al.Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis[J].J Hepatol, 2004, 40 (1) :31-39.
|
[19]XU Y, WANG JB, WANG S, et al.Association between chronic urinary tract infection and primary biliary cirrhosis[J].Chin J Hepatol, 2016, 24 (6) :478-480 (in Chinese) 徐严, 王江滨, 王颂, 等.慢性泌尿系感染与原发性胆汁性肝硬化的关系[J].中华肝脏病杂志, 2016, 24 (6) :478-480.
|
[20]JIANG XH, ZHONG RQ, FANG XY, et al.Establishment of a mouse model of primary biliary cirrhosis by AMA M2 autoantigen injection[J].Chin J Hepatol, 2006, 14 (3) :202-204. (in Chinese) 姜小华, 仲人前, 方晓云, 等.抗线粒体抗体M2抗原诱导小鼠原发性胆汁性肝硬化模型的建立[J].中华肝脏病杂志, 2006, 14 (3) :202-204.
|
[21] BOGDANOS DP, BAUM H, GRASSO A, et al.Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis[J].J Hepatol, 2004, 40 (1) :31-39.
|
[22]YANG GX, LIAN ZX, CHUANG YH, et al.Adoptive transfer of CD8 (+) T cells from transforming growth factor beta receptor type II (dominant negative form) induces autoimmune cholangitis in mice[J].Hepatology, 2008, 47 (6) :1974-1982.
|
[23]BERNUZZI F, FENOGLIO D, BATTAGLIA F, et al.Phenotypical and functionalalterations of CD8 regulatory T cells in primary biliary cirrhosis[J].J Autoimmun, 2010, 35 (3) :176-180.
|
[24]FENOGLIO D, BERNUZZI F, BATTAGLIA F, et al.Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases[J].Autoimmun Rev, 2012, 12 (2) :300-304.
|
[25]OERTELT S, LIAN ZX, CHENG CM, et al.Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor IIdominant-negative mice[J].J Immunol, 2006, 177 (3) :1655-1660.
|
[26]KOARADA S, WU Y, CHENG CM, et al.Genetic control of autoimmunity:protection from diabetes, but spontaneous autoimmune biliary disease in a nonobese diabetic congenic strain[J].J Immunol, 2004, 173 (4) :2315-2323.
|
[27]IRIE J, WU Y, WICKER LS, et al.NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis[J].Exp Med, 2006, 203 (5) :1209-1219.
|
[28]KATSUMI T, TOMITA K, LEUNG PS, et al.Animal models of primary biliary cirrhosis[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :142-153.
|
[29]MORITOKI Y, TSUDA M, TSUNEYAMA K, et al.B cells promote hepatic inflammation, biliary cyst formation, and salivary gland inflammation in the NOD.c3c4 model of autoimmune cholangitis[J].Cell Immunol, 2011, 268 (1) :16-23.
|
[30]YAO Y, YANG W, YANG YQ, et al.Distinct from its canonical effects, deletion of IL-12p40 induces cholangitis and fibrosis in interleukin-2Ralpha (-/-) mice[J].J Autoimmun, 2014, 51 (4) :99-108.
|
[31]HSU W, ZHANG W, TSUNEYAMA K, et al.Differential mechanisms in the pathogenesis of autoimmune cholangitis versus inflammatory bowel disease in interleukin-2Ralpha (-/-) mice[J].Hepatology, 2009, 49 (1) :133-140.
|
[32]LLEO A, OERTELT-PRIGIONE S, BIANCHI I, et al.Y chromosome loss in male patients with primary biliary cirrhosis[J].JAutoimmun, 2013, 41:87-91.
|
[33]CHEN XM, O'HARA SP, LARUSSO NF, et al.The immunobiology of cholangiocytes[J].Immunol Cell Biol, 2008, 86 (6) :497-505.
|
[34]SALAS JT, BANALES JM, SARVIDE S, et al.Ae2a, b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis[J].Gastroenterology, 2008, 134 (5) :1482-1493.
|
[35]LLEO A, ZHANG W, ZHAO M, et al.DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3promoter in primary biliary cirrhosis[J].Clin Epigenetics, 2015, 7 (1) :61.
|
[1] | Zongqi DENG, Wenlin TAI. Role of macrophages in the development and progression of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1924-1928. doi: 10.12449/JCH240932 |
[2] | Qiupeng WANG, Meifu GAN. Pathological diagnosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2024, 40(6): 1088-1092. doi: 10.12449/JCH240604 |
[3] | Yujie QIN, Wenxiu ZHOU, Xingnian ZHOU, Mingliang CHENG, Hong LI. Report and genetic analysis of autoimmune liver diseases between mother and daughter[J]. Journal of Clinical Hepatology, 2023, 39(2): 387-391. doi: 10.3969/j.issn.1001-5256.2023.02.021 |
[4] | Lin HAN, Qingsheng LIANG, Huan XIE, Ying CHEN, Jun ZHAO, Mingyue ZHANG, Baosen LI, Yanli DONG, Ying SUN. Value of baseline IgM level in predicting the treatment response of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(4): 815-820. doi: 10.3969/j.issn.1001-5256.2022.04.015 |
[5] | Xinhang SONG, Juanhan YU, Zhaoping CHENG, Chen SHAO, Baocheng DENG. Pathological staging systems of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(3): 653-655. doi: 10.3969/j.issn.1001-5256.2022.03.033 |
[6] | Fang QIU, Chan WANG, Mingming ZHANG, Xingjuan SHI, Xiangdong LIU. Genetic studies of primary biliary cholangitis in the post-GWAS era[J]. Journal of Clinical Hepatology, 2022, 38(4): 759-761. doi: 10.3969/j.issn.1001-5256.2022.04.005 |
[7] | Xing LYU, Ting LI, Xiaodong SUN, Jianpeng ZHOU, Dongxia WANG, Guoyue LYU. Research advances in the treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(9): 2130-2135. doi: 10.3969/j.issn.1001-5256.2022.09.035 |
[8] | Haitao MA, Yingmei TANG. Research advances in exosomes in primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1896-1900. doi: 10.3969/j.issn.1001-5256.2022.08.035 |
[9] | Jing ZHU, Yanhang GAO. Recommendations for APASL clinical practice guidance: The diagnosis and management of patients with primary biliary cholangitis (2022)[J]. Journal of Clinical Hepatology, 2022, 38(2): 318-319. doi: 10.3969/j.issn.1001-5256.2022.02.012 |
[10] | Ma WeiYu, Deng ZhiHua. Current status of immunogenetic studies on primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(4): 932-935. doi: 10.3969/j.issn.1001-5256.2020.04.050 |
[11] | Huang ZhiQin, Huang HuiFang. Research advances in cytokines associated with primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2020, 36(2): 446-450. doi: 10.3969/j.issn.1001-5256.2020.02.047 |
[12] | Tu RongFang, Yang Xue, Tang YingMei. Research advances in primary biliary cholangitis with extrahepatic autoimmune diseases[J]. Journal of Clinical Hepatology, 2020, 36(6): 1398-1401. doi: 10.3969/j.issn.1001-5256.2020.06.046 |
[13] | Xu Li, Zheng YueQi, Shi Zhen, Chen YiYun, Shao HuiJiang, Chen JianJie. Influencing factors for the prognosis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(8): 1870-1873. doi: 10.3969/j.issn.1001-5256.2019.08.050 |
[14] | Qu Yao, Zhang Wei. Role of cell apoptosis in the pathogenesis of primary biliary cholangitis[J]. Journal of Clinical Hepatology, 2019, 35(6): 1397-1400. doi: 10.3969/j.issn.1001-5256.2019.06.049 |
[15] | Li ShuXiang, Duan WeiJia, Zhang Dong, You Hong, Jia JiDong. Research advances in autoimmune hepatitis and primary biliary cholangitis in 2017[J]. Journal of Clinical Hepatology, 2018, 34(7): 1569-1572. doi: 10.3969/j.issn.1001-5256.2018.07.044 |
[16] | Li Dong, Lu ZhongHua, Gan JianHe. Establishment of a rat model of early-stage liver failure and Th17/Treg imbalance[J]. Journal of Clinical Hepatology, 2016, 32(5): 928-932. doi: 10.3969/j.issn.1001-5256.2016.05.025 |
[17] | Fan ZhiDong, You JinLi. Diagnosis and treatment procedure for intractable liver ascites[J]. Journal of Clinical Hepatology, 2015, 31(3): 472-474. doi: 10.3969/j.issn.1001-5256.2015.03.039 |
[18] | Huang HaiYan, Xin YongNing, Jiang Man, Jin WenWen, Jiang XiangJun, Xuan ShiYing. Research advances in animal models of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2014, 30(9): 948-953. doi: 10.3969/j.issn.1001-5256.2014.09.028 |
[19] | Sun LinLin, Shi Jun, Hao JingHua, Ren WanHua, Yan ChunYing, Zhang Jie, Lin XiaoYan, Cui Bin. Effect of high-fat diet on establishment of a rat non-alcoholic steatohepatitis/liver fibrosis model[J]. Journal of Clinical Hepatology, 2011, 27(3): 254-257+272. |
[20] | Lou GuoHua, Liu YanNing, Yin ChunBen, Chen Feng, Jia ZhanSheng, Chen Zhi. Preliminary study of HCV mouse model induced by infectious HCV 2a plasmid[J]. Journal of Clinical Hepatology, 2011, 27(1): 72-75. |